1-16 of 16
Jan Scicinski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4358: The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry

Free
Hongjuan Zhao, Shoucheng Ning, Rosalie Nolley, Jan Scicinski, Bryan Oronsky, Susan J. Knox, Donna M. Peehl
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4358.
https://doi.org/10.1158/1538-7445.AM2017-4358
Published: 01 July 2017
View article titled, Abstract 4358: The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry
Journal Articles

Abstract 966: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis

Free
Saheli Jha, Thomas A. Summers, Karen Zeman, Christine Brzezniak, Corey Carter, Lindsey Ferry, Jan Scicinski, Bryan Oronsky, Scot Caroen, Jane B. Trepel, Pedro Cabrales, Regina Day
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 966.
https://doi.org/10.1158/1538-7445.AM2017-966
Published: 01 July 2017
View article titled, Abstract 966: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis
Journal Articles

Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001

Free
Pedro Cabrales, Bryan Oronsky, Jan Scicinski
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2165.
https://doi.org/10.1158/1538-7445.AM2016-2165
Published: 15 July 2016
View article titled, Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001
Journal Articles

Abstract 1245: RRx-001 is effective in temozolomide-sensitive and resistant GBM

Free
Veronica Steri, Bryan Oronsky, Jan Scicinski, Gabriele Bergers
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1245.
https://doi.org/10.1158/1538-7445.AM2016-1245
Published: 15 July 2016
View article titled, Abstract 1245: RRx-001 is effective in temozolomide-sensitive and resistant GBM
Journal Articles

Abstract 4916: Improved statistical approaches that account for pseudoprogression in preclinical studies of RRx-001 with immunotherapies

Free
Nacer E. Abrouk, Jan Scicinski, Bryan Oronsky, Susan J. Knox, Donna Peehl, Shoucheng Ning, Gary R. Fanger
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4916.
https://doi.org/10.1158/1538-7445.AM2016-4916
Published: 15 July 2016
View article titled, Abstract 4916: Improved statistical approaches that account for pseudoprogression in preclinical studies of RRx-001 with immunotherapies
Journal Articles

Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET

Free
Tony Reid, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Bryan Oronsky, Gary Fanger, Meaghan Stirn, Scott Caroen, Christopher Parker, Jan Scicinski
Journal: Cancer Research
Cancer Res (2016) 76 (2_Supplement): B26.
https://doi.org/10.1158/1538-7445.CHROMEPI15-B26
Published: 14 January 2016
View article titled, Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET
Journal Articles

Abstract A1-35: RRx-001, a novel first in class epigenetic modulator, “episensitizes” colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study

Free
Tony Reid, Jennifer Carney, Keola Beale, Chan Clayton, Huy Nguyen, Cheryl Cho-Phan, Meaghan Stirn, Shoucheng Ning, Susan Knox, Bryan Oronsky, Jan Scicinski, Scott Caroen, Christopher Parker, Gary R. Fanger, George Fisher
Journal: Cancer Research
Cancer Res (2015) 75 (22_Supplement_1): A1-35.
https://doi.org/10.1158/1538-7445.TRANSCAGEN-A1-35
Published: 15 November 2015
View article titled, Abstract A1-35: RRx-001, a novel first in class epigenetic modulator, “episensitizes” colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
Journal Articles

Abstract 3515: RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy

Free
Hongjuan Zhao, Shoucheng Ning, Jan Scicinski, Bryan Oronsky, Susan Knox, Donna M. Peehl
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3515.
https://doi.org/10.1158/1538-7445.AM2015-3515
Published: 01 August 2015
View article titled, Abstract 3515: RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy
Journal Articles

Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer

Free
Tony Reid, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Bryan Oronsky, Gary R. Fanger, Scott Caroen, Christopher Parker, Jan Scicinski
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT119.
https://doi.org/10.1158/1538-7445.AM2015-CT119
Published: 01 August 2015
View article titled, Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
Journal Articles

Abstract 906: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice

Free
Shoucheng Ning, Thillai Veerapazham Sekar, Ramasamy Paulmurugan, Jan Scicinski, Bryan Oronsky, Donna Peehl, Susan J. Knox
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 906.
https://doi.org/10.1158/1538-7445.AM2014-906
Published: 01 October 2014
View article titled, Abstract 906: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice
Journal Articles

Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase

Free
Pedro Cabrales, Bryan Oronsky, Jan Scicinski
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1420.
https://doi.org/10.1158/1538-7445.AM2014-1420
Published: 01 October 2014
View article titled, Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Journal Articles

Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models

Free
Natarajan Raghunand, Jan Scicinski, Bryan Oronsky, Gerald Guntle, Elizabeth Bruckheimer, Ron Korn
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2068.
https://doi.org/10.1158/1538-7445.AM2014-2068
Published: 01 October 2014
View article titled, Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models
Journal Articles

Abstract LB-86: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent.

Free
Tony Reid, Jeffrey R. Infante, Asit Paul, Howard A. Burris, Bryan Oronsky, Curtis Scribner, Susan Knox, Janet Stephens, John Santini, Jan Scicinski
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-86.
https://doi.org/10.1158/1538-7445.AM2013-LB-86
Published: 15 April 2013
View article titled, Abstract LB-86: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent.
Journal Articles

Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials

Free
Shoucheng Ning, Mark Bednarski, Bryan Oronsky, Jan Scicinski, Gordon Saul, Susan J. Knox
Journal: Cancer Research
Cancer Res (2012) 72 (10): 2600–2608.
https://doi.org/10.1158/0008-5472.CAN-11-2303
Published: 14 May 2012
View article titled, Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials
Open the PDF for Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials in another window
Journal Articles

Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors

Free
Jan Scicinski, Bryan Oronsky, Shoucheng Ning, Andrew Minchinton, Susan Knox
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4371.
https://doi.org/10.1158/1538-7445.AM2012-4371
Published: 15 April 2012
View article titled, Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors
Journal Articles

Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials

Free
Shoucheng Ning, Mark Bednarski, Bryan Oronsky, Jan Scicinski, Gordon Saul, Susan J. Knox
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 676.
https://doi.org/10.1158/1538-7445.AM2011-676
Published: 15 April 2011
View article titled, Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials